02:26 PM EST, 12/09/2024 (MT Newswires) -- GSK (GSK) said a phase 3 trial showed a "statistically significant and clinically meaningful overall survival" for the belantamab mafodotin combination versus the daratumumab combination as a second line or later treatment for relapsed or refractory multiple myeloma.

After a median follow-up of 39.4 months, the analysis showed a 42% lower risk of death for patients receiving the belantamab mafodotin combination compared with those on the daratumumab-based treatment, the company said Monday in a statement.

The safety and tolerability of the belantamab mafodotin regimen were in line with the primary analysis and the known safety profiles of the individual drugs used, the company said.

The planned interim analysis builds on data from earlier studies, which showed significant improvements in progression-free survival for both belantamab mafodotin-based combinations versus standard of care, the company said.

Shares of GSK rose 4% in recent trading Monday.

Price: 35.96, Change: +1.39, Percent Change: +4.01